HCG Healthcare Global Enterprises Q4 FY26 results (Jan–Mar 2026) and concall
Health.Global reported a strong FY26 with 15% revenue growth and 19% adjusted EBITDA growth, driven by improved utilization and strategic focus on oncology. The company strengthened its balance sheet through a ₹425 crore rights issue and divested its non-core fertility business, Milann, for ₹63 crores. While Q4 revenue growth was moderated by strategic shifts and external factors, management expressed confidence in continued profitable growth and margin expansion, targeting 1,000 new beds by FY30 and 20% ROCE in 4-5 years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 11.5%, net profit down 42.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 554 | 559 | 585 | 613 | 647 +17% | 633 +13% | 652 +11% |
| EBITDA | 102 | 88 | 106 | 108 | 123 +21% | 110 +25% | 125 +18% |
| Net profit | 21 | 8 | 7 | 6 | 21 +0% | -8 −200% | 4 −43% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
